Friday, 13 November 2026European Markets

AZERION Stock Bullish By 9% So Far On Tuesday

Loading stream...

Today saw a crucial development in the stocks of a major tech company that has been experiencing some lows. Shares of the company, Azerion (AEX-Index: AZRN.AS), rose 9.244% to EUR2.60, providing some relief after the last session's downward trend. Despite this, the overall AEX-Index fell 0.27%, standing at EUR789.90.

About Azerion

Azerion recently closed at EUR2.38, marking an 81.873% drop from its 52-week peak of EUR8.46. Established in 2014 and based in the Netherlands, the company specializes in digital entertainment and media. Azerion offers technology solutions for managing digital advertising inventory while developing social and casual games online.

Azerion's Profitability

If we look into Azerion's profitability, it had trailing twelve-month earnings per share (EPS) of EUR-0.1. Additionally, its return on equity (ROE), an indicator of how profitable the relative shareholder equity was, stood negative at -25.21% for the same period.

Stability and Performance of Azerion's Stocks

Despite the negative profitability, Azerion's current stock value of EUR2.60 is a bit higher than its 50-day moving average of EUR2.44, suggesting a possible investor interest. However, it is significantly below its 200-day moving average of EUR3.51.

Azerion's Operational Performance

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization), a measure of operational performance, was recorded at 74.03 on September 17. The last reported volume on the trading day was 223,475. This mark represents a 5.35% increase from its average daily volume of 212,117, indicating escalated trading activity.

Outlook

In conclusion, Azerion's shares have been trading at significant lows recently. However, the recent uptick and increased trading activity may be a sign of renewed investor interest in these shares. Nonetheless, potential investors should remain aware of Azerion's negative profitability indicators and market fluctuations before investing.

More news about AZERION (AZRN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com